
LogicBio Therapeutics LOGC
LogicBio Therapeutics Total Liabilities | LOGC
Annual Total Liabilities LogicBio Therapeutics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 32 M | 19.2 M | 13.4 M | 2.68 M | 1.71 M | 5.28 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 32 M | 1.71 M | 12.4 M |
Quarterly Total Liabilities LogicBio Therapeutics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 22.9 M | 26.3 M | 27 M | 32 M | 29.4 M | 33.1 M | 19.7 M | 19.2 M | 19.5 M | 19.2 M | 15 M | 13.4 M | 13.9 M | 13.4 M | 3.82 M | 2.68 M | 2.55 M | - | 2.68 M | 1.71 M | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 33.1 M | 1.71 M | 16 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aldeyra Therapeutics
ALDX
|
27.8 M | $ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
53.4 M | $ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
2.08 B | $ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
64.9 M | $ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
62.2 M | $ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
683 M | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
35.1 M | $ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
16.5 M | $ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
2.76 B | $ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
668 M | $ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
900 M | $ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
15.6 M | $ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
109 M | $ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
58.7 M | $ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
123 M | $ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
55 M | $ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
30.2 M | $ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
1.47 B | $ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
57.2 M | $ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
170 M | $ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
411 M | $ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
39.8 M | $ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
602 M | $ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
3.01 B | $ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
633 M | $ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
108 M | $ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
5.61 M | $ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
2.08 M | $ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
1.53 B | $ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
215 M | $ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
4.7 M | $ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
1.96 M | $ 15.56 | 13.57 % | $ 64.8 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.76 B | $ 12.36 | -9.55 % | $ 799 M | ||
|
Immutep Limited
IMMP
|
13.3 M | $ 3.11 | -9.06 % | $ 4.53 B | ||
|
Jazz Pharmaceuticals plc
JAZZ
|
2.43 B | $ 228.26 | -3.46 % | $ 13.9 B | ||
|
BeyondSpring
BYSI
|
49.9 M | $ 0.33 | -24.42 % | $ 13.6 M | ||
|
Cabaletta Bio
CABA
|
53 M | $ 0.94 | -7.24 % | $ 94.5 M | ||
|
Johnson & Johnson
JNJ
|
118 B | $ 270.2 | 1.18 % | $ 650 B | ||
|
Cue Biopharma
CUE
|
15.8 M | $ 4.2 | -6.67 % | $ 398 M | ||
|
C4 Therapeutics
CCCC
|
102 M | $ 2.49 | 1.84 % | $ 206 M | ||
|
Codexis
CDXS
|
97.3 M | $ 1.0 | -5.17 % | $ 87.1 M | ||
|
Kamada Ltd.
KMDA
|
32 M | $ 7.75 | -1.02 % | $ 447 M | ||
|
Compugen Ltd.
CGEN
|
18.5 M | $ 1.83 | -2.66 % | $ 171 M | ||
|
Coherus BioSciences
CHRS
|
197 M | $ 0.37 | -4.06 % | $ 43.3 M | ||
|
Armata Pharmaceuticals
ARMP
|
295 M | $ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
55.8 M | $ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
249 M | $ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
69.2 M | $ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
1.83 M | $ 2.01 | -7.59 % | $ 11.4 M |